share_log

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bassler Bonnie L

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bassler Bonnie L

再生元製藥公司 | 4:持股變動聲明-董事 Bassler Bonnie L
美股SEC公告 ·  01/07 05:09

Moomoo AI 已提取核心訊息

On January 2, 2025, Bonnie L Bassler, a director at Regeneron Pharmaceuticals, was granted 166 shares of Common Stock at $0 per share. This transaction was reported as a direct acquisition under the transaction code 'A', indicating a grant, award, or other acquisition.Following this transaction, Bassler's direct ownership of Regeneron Common Stock increased to 1,548 shares. The acquisition was completed on the reported date, with no additional transactions mentioned in the filing. This grant appears to be part of the company's equity compensation program for directors.
On January 2, 2025, Bonnie L Bassler, a director at Regeneron Pharmaceuticals, was granted 166 shares of Common Stock at $0 per share. This transaction was reported as a direct acquisition under the transaction code 'A', indicating a grant, award, or other acquisition.Following this transaction, Bassler's direct ownership of Regeneron Common Stock increased to 1,548 shares. The acquisition was completed on the reported date, with no additional transactions mentioned in the filing. This grant appears to be part of the company's equity compensation program for directors.
在2025年1月2日,來自再生元製藥公司的董事邦妮·L·巴斯勒獲得了166股每股0美元的普通股。此次交易根據交易代碼「A」被報告爲直接收購,表明是授予、獎勵或其他收購。在此次交易之後,巴斯勒對再生元普通股的直接持有量增加至1,548股。該收購在報告日期完成,文件中未提及其他交易。此次授予似乎是公司爲董事們提供的股權補償計劃的一部分。
在2025年1月2日,來自再生元製藥公司的董事邦妮·L·巴斯勒獲得了166股每股0美元的普通股。此次交易根據交易代碼「A」被報告爲直接收購,表明是授予、獎勵或其他收購。在此次交易之後,巴斯勒對再生元普通股的直接持有量增加至1,548股。該收購在報告日期完成,文件中未提及其他交易。此次授予似乎是公司爲董事們提供的股權補償計劃的一部分。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息